arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Editas Medicine, Inc.

EDIT
$2.53 ▼ -0.21 (-7.66%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
13 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Editas Medicine, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $224.5M
Dividend Yield —
Revenue Growth 25.4% ↗
Op. Margin -394.9%
ROIC -156.3% ↘
FCF / Share $-1.87 ↗
Trailing P/E —
Price / Book 9.1x
FCF Yield —
Debt / Equity 1.96
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.52M
↑ +25.4% —
Net Income Profit after all expenses
$-160.06M
↑ +32.5% —
Operating Margin Operating profit as % of sales
-394.9%
↓ -82.3% 0th
FCF / Share Free cash flow per share
$-1.87
↑ +29.8% —
Long-Term Debt Long-term obligations
$53.60M
↓ -6.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Financial Health ↑
17
Cash Quality ↑
67

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 48 quarters